- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01031212
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase I 3+3 dose escalation design in patients with solid tumors who have been previously treated with chemotherapy or for whom no standard treatment options exist. Carboplatin, paclitaxel and cetuximab will be administered in standard doses. The dose of ASA404 will be escalated under predefined levels. One treatment cycle constitutes 3 weeks. A minimum of 3 patients will be entered at each treatment level, to be expanded to 6 subjects if dose limiting toxicities (DLT) are observed. If no more than one in six patients has DLT, additional patients will be enrolled at a higher dose. Once a maximum tolerated dose (MTD) has been established, the tolerability of this dose will be tested in a total of 12 patients. The anticipated sample size is 18-24 patients.
Carboplatin and paclitaxel are chosen as the chemotherapy back bone since they are commonly used in combination in multiple tumors. Cetuximab has been chosen as the EGFR inhibitor because the combination of platinum based therapy with cetuximab is effective in lung and head and neck cancers. In addition the safety and activity of carboplatin/paclitaxel with ASA 404 has already been demonstrated. A weekly schedule of ASA is chosen because 1) the safety of the weekly schedule has been tested 2) preclinical studies confirm enhanced activity with frequent administration 3) provides an opportunity to evaluate the safety and pharmacokinetics of ASA 404 with weekly cetuximab.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological confirmed malignancy of advanced, incurable solid tumor
- Progression following standard therapy, or no acceptable standard treatment options, or eligible if standard therapy consists of a platinum-based doublet
- Measurable or evaluable disease. Measurable disease required for enrollment in dose expansion cohort at MTD
- ECOG 0-2
- Baseline neuropathy grade ≤ 1
- leukocytes >3,000/mcL
- absolute neutrophil count >1,500/mcL
- platelets >100,000/mcL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) <1.5 X institutional ULN
- creatinine within 1.5 x normal institutional limits OR creatinine clearance >60 mL/min/1.73 m2
- Ability to give written informed consent and willingness to comply with requirements of the protocol
- Women of child-bearing potential must have a negative pregnancy test within 14 days of beginning study drug and agree to use an effective method of birth control during treatment and for six months after last dose of study drug
- Male patients whose sexual partners are women of reproductive potential must be surgically sterile or agree to use a double method of contraception during the study and for six months after last dose of study drug. One of method must be a condom
- Patients with known brain metastases should have "stable disease" defined as no growth over a 6 week period after definitive therapy (surgical or RT), and off steroids and anticonvulsive therapy
Exclusion Criteria:
- Chemotherapy, hormonal therapy or biologic therapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the start of study therapy or not recovered to < grade 2 from adverse events due to prior agents
- Prior therapy with EGFR inhibitors is permitted
- Patients receiving palliative radiation therapy <2 weeks earlier. Patients must have recovered from all toxicities of radiation
- Receiving any other investigational agents
- Any severe and/or uncontrolled intercurrent medical conditions or other conditions that could affect participation in the study
- Any of the following cardiac abnormalities: unstable angina pectoris, including Prinzmetal variant angina, New York Heart Association (NYHA) Classification for Congestive Heart Failure Grade III or greater, myocardial infarction or stroke ≤ 12 months prior to study treatment, long QT syndrome, baseline 12 lead ECG QTc of >450msec per central evaluation, history of sustained ventricular tachycardia, history of ventricular fibrillation or Torsades de Pointes, right bundle branch block and left anterior hemiblock (bifascicular block), bradycardia (<50 beats per minute)
- Concomitant use of drugs with a risk of causing Torsades de Pointes
- PT/PTT > 1.5 x ULN
- Receiving full-dose anticoagulation (low-dose warfarin for a central line allowed)
- History of another primary malignancy less than 5 years prior, except non-melanoma skin cancer or cervical cancer in-situ
- Major surgery ≤ 4 weeks prior (requiring general anesthesia or respiratory assistance)(endoscopic exams with diagnostic intent allowed)
- Minor surgery ≤ 2 weeks prior (not requiring general anesthesia or respiratory assistance)
- Insertion of vascular access device allowed
- Not recovered from surgery-related complications
- Systolic BP >160mmHg and/or diastolic BP >90mmHg while on medication for hypertension
- Hemoptysis associated with chest malignancy <4 weeks (>1 teaspoon)
- History of hypersensitivity reactions to TAXOL or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil)
- History of severe allergic reactions to cisplatin or other platinum-containing compounds
- History of acute hemorrhagic events requiring hospital admission or blood transfusion
- Pregnant or lactating women
- Fertile women and men not willing to comply with birth control instructions
- Any condition that compromises compliance with objectives and procedures of this protocol, as judged by the principal investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose (MTD)
Time Frame: During cycle 1 (4 weeks)
|
During cycle 1 (4 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number and percentage of subjects experiencing one or more AEs will be summarized by dose cohort, relationship to study drug, and severity
Time Frame: Within 30 days after study treatment, or until resolution of AE
|
Within 30 days after study treatment, or until resolution of AE
|
Pharmacokinetics of ASA404 in combination with other agents
Time Frame: 48 hours after cycle 1, day 1
|
48 hours after cycle 1, day 1
|
Disease response by RECIST criteria
Time Frame: until progression
|
until progression
|
Assess biological correlates of antitumor activity by measuring serum 5HIAA, VEGF, bFGF, PLGF, sVEGFR2, FGF 23, serum apoptotic markers (M30/M65)
Time Frame: 4 weeks after treatment end
|
4 weeks after treatment end
|
DNA analysis of FGFR1 and VEGF polymorphism
Time Frame: 4 weeks after treatment ends
|
4 weeks after treatment ends
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sarita Dubey, MD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Anti-Bacterial Agents
- Carboplatin
- Paclitaxel
- Cetuximab
- Acetic Acid
- Vadimezan
Other Study ID Numbers
- UCSF-09997
- H53469-35218 (OTHER: UCSF Committee on Human Research)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMalignant Tumors | Refractory TumorsFrance
-
AmgenCompletedSolid Tumors | Oncology | Tumors
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
OncoMed Pharmaceuticals, Inc.CompletedRefractory Solid Tumors | Advanced Relapsed TumorsUnited States
-
Baylor College of MedicineHarris County Hospital District; The Methodist Hospital Research InstituteWithdrawn
Clinical Trials on ASA404
-
Novartis PharmaceuticalsTerminatedHistologically-proven and Radiologically-confirmed Solid TumorsItaly, New Zealand
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsTerminatedMetastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal FunctionBelgium
-
Novartis PharmaceuticalsCompletedAdvanced or Recurrent Solid TumorsJapan
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsTerminatedNon-Small Cell Lung CancerUnited States, Germany, Belgium, Italy, France, Canada, Hungary, Poland, Switzerland, Spain
-
Hoosier Cancer Research NetworkNovartis PharmaceuticalsWithdrawnUrothelial Carcinoma
-
Novartis PharmaceuticalsTerminatedNon-Small Cell Lung CancerUnited States, Greece, Hong Kong, Taiwan, Argentina, Germany, United Kingdom, Singapore, Italy, Spain, France, Korea, Republic of, Netherlands, Brazil, Canada, Turkey, China, New Zealand, Hungary, Poland, Australia, Japan, Israel, Bel... and more